Results 171 to 180 of about 34,931 (220)
, 2019 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Endocrine Reviews, 2014
Adrenocortical carcinoma is a rare endocrine tumor with a poor prognosis. These tumors can be diagnostically challenging, and diagnostic algorithms and criteria continue to be suggested. Myxoid and oncocytic variants are important to recognize to not confuse with other tumors.
Tobias Else +2 more
exaly +3 more sources
Adrenocortical carcinoma is a rare endocrine tumor with a poor prognosis. These tumors can be diagnostically challenging, and diagnostic algorithms and criteria continue to be suggested. Myxoid and oncocytic variants are important to recognize to not confuse with other tumors.
Tobias Else +2 more
exaly +3 more sources
Journal of Urology, 2008
Adrenocortical carcinoma (ACC) is a rare cancer with a generally poor prognosis. In approximately 60% of cases the initial clinical manifestations are due to hypersecretion of adrenocortical hormones. Cushing's syndrome is the most frequent hormonal manifestation.
Camil J, Chouairy +2 more
openaire +4 more sources
Adrenocortical carcinoma (ACC) is a rare cancer with a generally poor prognosis. In approximately 60% of cases the initial clinical manifestations are due to hypersecretion of adrenocortical hormones. Cushing's syndrome is the most frequent hormonal manifestation.
Camil J, Chouairy +2 more
openaire +4 more sources
Surgical Oncology Clinics of North America, 2006
ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with the improvement in patient survival. Even with appropriated diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete ...
Steven E, Rodgers +3 more
openaire +4 more sources
ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with the improvement in patient survival. Even with appropriated diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete ...
Steven E, Rodgers +3 more
openaire +4 more sources
Endocrinology and Metabolism Clinics of North America, 2015
Recent developments in the treatment of adrenocortical carcinoma (ACC) include diagnostic and prognostic risk stratification algorithms, increasing evidence of the impact of historical therapies on overall survival, and emerging targets from integrated epigenomic and genomic analyses.
Baudin,Eric +16 more
+6 more sources
Recent developments in the treatment of adrenocortical carcinoma (ACC) include diagnostic and prognostic risk stratification algorithms, increasing evidence of the impact of historical therapies on overall survival, and emerging targets from integrated epigenomic and genomic analyses.
Baudin,Eric +16 more
+6 more sources
Virilising adrenocortical carcinoma
BMJ Case Reports, 2021Adrenocortical carcinoma (ACC) is a rare malignancy, with an estimated annual incidence of 0.7–2 cases per million and a median overall survival of 3–4 years. Hormone-secreting ACCs represent most cases; of these, only a small minority presents with virilisation alone. Early diagnosis is key to increase the chances of a better outcome.
Diogo Nunes, Correia +2 more
openaire +2 more sources
Urologic Clinics of North America, 1989
In reviewing the experience of a number of authors and investigators, it is clear that early diagnosis of adrenocortical carcinoma is essential for cure. Of all the modalities of therapy currently available, surgical resection holds the most promise for cure or prolonged survival.
J I, Barzilay, A G, Pazianos
openaire +2 more sources
In reviewing the experience of a number of authors and investigators, it is clear that early diagnosis of adrenocortical carcinoma is essential for cure. Of all the modalities of therapy currently available, surgical resection holds the most promise for cure or prolonged survival.
J I, Barzilay, A G, Pazianos
openaire +2 more sources
World Journal of Urology, 1999
Abstract Adrenocortical carcinoma is a rare tumor with an annual incidence of between 0.5 and 2 cases per million (Brennan 1987; National Cancer Institute 1975). This is in contrast to the incidence of adenomas of the adrenal gland yielding a relatively frequent finding of an ‘ incidentaloma’ in patients having cross- sectional imaging ...
R D, Schulick, M F, Brennan
openaire +2 more sources
Abstract Adrenocortical carcinoma is a rare tumor with an annual incidence of between 0.5 and 2 cases per million (Brennan 1987; National Cancer Institute 1975). This is in contrast to the incidence of adenomas of the adrenal gland yielding a relatively frequent finding of an ‘ incidentaloma’ in patients having cross- sectional imaging ...
R D, Schulick, M F, Brennan
openaire +2 more sources